Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 8;13(1):197.
doi: 10.1186/s13023-018-0944-x. Print 2018 Oct 26.

Mapping health care of rare diseases: the example of epidermolysis bullosa in Germany

Affiliations

Mapping health care of rare diseases: the example of epidermolysis bullosa in Germany

Antonia Reimer et al. Orphanet J Rare Dis. .

Abstract

Background: Rare diseases affect approximately 30 million people in the European Union and present a major health issue. Over 1000 rare skin diseases are known, many of which are of genetic origin and manifest in childhood. One of these diseases is epidermolysis bullosa (EB), a genodermatosis presenting with skin fragility and blistering. With an estimate of up to 2000 affected individuals in Germany, many of these children, but only two specialist centres, the question arose where and how health care for this rare disease is provided. This question was addressed by an online survey of all paediatric and dermatological departments in Germany.

Results: The response rate was 40.5% (203/501), and 39 departments confirmed treating EB (7.8% of the units addressed). Health care for individuals with EB was provided both by dermatological and paediatric departments (19.8 and 4.2% respectively). The geographic distribution of EB health care was uneven. The two EB centres in Hanover and Freiburg treated 70 and 113 patients, two other departments saw 11 to 20 patients, while the majority saw less than 10 patients annually. There existed large variations between 1. the consultation setting, time frame and frequency, 2. the recommended examinations and check-ups and 3. the diagnostics used to establish the diagnosis. Over 50% of participating physicians were dissatisfied with health care outside of hospitals and more than 20% with their patients' supply with bandages or medications.

Conclusions: The survey results show that health care for individuals with EB in Germany is provided multidisciplinarily. Approaches to diagnostics and follow-up recommendations are heterogeneous and national guidelines are lacking. Functioning and innovative political structures are needed to improve networking and strengthening specialised centres to meet the special needs of individuals with EB and other rare diseases.

Keywords: Epidermolysis bullosa; Genodermatoses; Health care; Paediatric dermatology; Rare disease; Survey.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study was approved by the ethics committee of the University of Freiburg (vote Nr. 461/17).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flowchart of the survey response
Fig. 2
Fig. 2
Geographical location of all survey participants according to specialisation of their clinic (Department of Dermatology, Paediatrics or rehabilitation hospitals) and the provision of care for individuals with EB (yes = red, no = blue)
Fig. 3
Fig. 3
Geographical location of survey participants that confirmed to provide care for individuals with EB. Symbol size indicates the number of patients treated annually, symbol shape indicates the clinics’ specialisations. In some cities, several departments or hospitals are involved in EB care; this is visualised by overlay of symbols. Note that only 2 hospitals indicated the care for > 40 patients each (Freiburg 113, Hanover 70 patients) and 2 for 11–20 patients (Erlangen, Berlin)
Fig. 4
Fig. 4
Number of individuals with EB per subtype and age group treated by survey participants during the previous twelve months
Fig. 5
Fig. 5
Average time (minutes) available per EB consultation (a) and physicians’ satisfaction regarding the average time (minutes) available per EB consultation (b). Numerical answers to consultation times were available from 27/39 participants
Fig. 6
Fig. 6
Medical subspecialties involved in EB care. a Overall response (n = 39). b Responses of departments for Dermatology (n = 21), c Departments for Paediatrics (n = 16). Replies on medical subspecialties in rehabilitation hospitals were only available for one of two hospitals, and only a dermatologist was regularly involved in EB care in this hospital
Fig. 7
Fig. 7
Medical history and clinical parameters collected during visits of EB patients. Anthropometric parameters include weight, height and calculation of percentiles
Fig. 8
Fig. 8
Participants’ recommendations regarding frequency of various examinations in EB-patients with generalised disease. *Additional to paediatric check-ups according to national health plan
Fig. 9
Fig. 9
Participants’ practices and recommendations regarding the frequency of specific laboratory measurements

References

    1. Commission on the European communities . Communication from the commission to the European parliament, the council, the European economic and social committee and the committee of the regions on Rare Diseases: Europe’s challenges {SEC (2008)2713} {SEC (2008)2712} 2008.
    1. European Commission . Implementation report on the commission communication on rare diseases: Europe’s challenges [COM (2008) 679 final] and council recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02) 2014.
    1. European Union Council recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02) Off J Eur Union. 2009;C 151:7–10.
    1. Schieppati A, Henter J-I, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008;371:2039–2041. doi: 10.1016/S0140-6736(08)60872-7. - DOI - PubMed
    1. Molster C, Urwin D, Di Pietro L, Fookes M, Petrie D, van der Laan S, et al. Survey of healthcare experiences of Australian adults living with rare diseases. Orphanet J Rare Dis. 2016;11:30. doi: 10.1186/s13023-016-0409-z. - DOI - PMC - PubMed